73 – Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide study of Cardiovascular Event Lowering (EXsCEL) – A.F. Hernandez, M.A. Bethel, G.L. Bakris, P. Merrill, S.M. Gustavson, B.G. Katona, P. Ohman, Y. Lokhnygina, R.J. Mentz, R.R. Holman, for the EXSCEL Study Group, USA, UK

74 – Liraglutide reduces major cardiovascular events in patients with chronic kidney disease: results from the LEADER trial – N. Poulter, J. Mann, V. Fonseca, O. Mosenzon, I. Raz, H. Frimer-Larsen, B. Von Scholten, T. Idorn, on behalf of the LEADER Trial Steering Committee and Investigators, UK, Germany, USA, Israel, Denmark

75 – Canagliflozin and cardiovascular outcomes in patients with chronic kidney disease – V. Perkovic, B.L. Neuen, T. Ohkuma, B. Neal, D.R. Matthews, D. De Zeeuw, K.W. Mahaffey, G. Fulcher, M. Desai, Q. Li, H. Deng, N. Rosenthal, M. Jardine, G. Bakris, Australia, UK, Netherlands, USA

76 – Lesser egFR decline with dulaglutide regardless of weight changes in people with type 2 diabetes and moderate to severe chronic kidney disease (AWARD-7) – K.R. Tuttle, M.C. Lakshmanan, B. Rayner, R.S. Busch, A.G. Zimmermann, D.B. Woodward, F.T. Botros, USA, South Africa

77 – Lixisenatide and renal outcomes in patients with type 2 diabetes: a post-hoc analysis of the ELiXA trial – M.H. Muskiet, H.J. Heerspink, L. Tonneijck, Y. Huang, M. Liu, A. Saremi, D.H. Van Raalte, Netherlands, USA

78 – Semaglutide treatment and renal function in the SUSTAIN 6 trial – R. Silver, J. Gumprecht, T. Vilsbøll, T. Hansen, J. Pettersson, H. Vrazic, J. Wilding, USA, Poland, Denmark, UK